What Makes Vaxcyte (PCVX) So Attractive

Vaxcyte Inc. (NASDAQ:PCVX) is one of the most promising mid-cap healthcare stocks under $50.

On December 9, BTIG analyst Thomas Shrader reiterated his bullish view of Vaxcyte Inc. (NASDAQ:PCVX). He assigned a Buy rating to the stock with a target price of $85. This results in an upside of over 83% from the current level.

Sharder mentioned the positive results from Phase 2 trials for the VAX-31 vaccine, which will prove to be a building block for the critical Phase 3 trials. The upcoming trial’s robust design involves a stringent success criterion involving a noninferiority margin for immunogenicity. This could ensure that VAX-31 would turn out to be a more effective cure for adult pneumococcal conditions.

Sharder also highlighted the target market for VAX-31, which ranges from ages 50 to 65 and offers potential for strong market adoption. The analyst views all these factors to place Vaxcyte Inc. (NASDAQ:PCVX) in a strong competitive position.

Even the consensus ratings also indicate analysts’ optimism about Vaxcyte Inc. (NASDAQ:PCVX). At the close of play on December 19, all 7 ratings assigned to the stock were Buy, with consensus forecasts showing a median 1-year price target of $100.80 per share. This offers investors a whopping 117.2% upside from the current trading levels.

Vaxcyte Inc. (NASDAQ:PCVX) is a company involved in the development of next-generation vaccines that offer protection against threatening bacterial diseases. Currently a clinical-stage company, Vaxcyte Inc. (NASDAQ:PCVX) deploys innovative synthetic methods and advanced chemistry to produce complex high-fidelity vaccines that contain enhanced immunological benefits.

READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.

Disclosure: None. This article is originally published at Insider Monkey.